R. Fossati

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

D. Katsaros, L. Cavanna, I. Meinhold-Heerlein, 2023, British Journal of Cancer.

Follow-up of colorectal cancer patients after resection with curative intent-the GILDA trial.

Katherine S. Virgo, W. Longo, F. Johnson, 2004, Surgical oncology.